Status: Recruiting
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design. It will consist in a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part.
Participants needed: 36
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Advanced BioDesignUpdated: Jan 20, 2025Locations: 3
Eligibility criteria
Patients with relapsed/refractory Acute Myeloid Leukemia (AML) after failing at... [+3]
Patients with acute myeloid leukemia (AML) with Inv(16) MYH11-CBF-Beta or t(8;21... [+16]